EdelmanJJBSecoMDunneB. Custodiol for myocardial protection and preservation: a systematic review. Ann Cardiothorac Surg2013; 2: 717–728.
4.
FremesSELevySLChristakisGT. Phase 1 human trial of adenosine-potassium cardioplegia. Circulation1996; 94: II370–II375.
5.
CohenGFeder-ElituvRIazettaJ. Phase 2 studies of adenosine cardioplegia. Circulation1998; 98: II225–II233.
6.
LiuRXingJMiaoN. The myocardial protective effect of adenosine as an adjunct to intermittent blood cardioplegia during open heart surgery. Eur J Cardio thorac Surg2009; 36: 1018–1023.
7.
MentzerRMBirjiniukVKhuriS. Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg1999; 229: 643–650.
8.
AhlssonASobrosaCKaijserL. Adenosine in cold blood cardioplegia – a placebo-controlled study. Interact CardioVasc Thorac Surg2012; 14: 48–55.
9.
JakobsenONæsheimTAasKN. Adenosine instead of supranormal potassium in cardioplegia: it is safe, efficient, and reduces the incidence of postoperative atrial fibrillation. A randomized clinical trial. J Thorac Cardiovasc Surg2013: 145: 812–818.
10.
SlootsKLDobsonGP. Normokalemic adenosine–lidocaine cardioplegia: importance of maintaining a polarized myocardium for optimal arrest and reanimation. J Thorac Cardiovasc Surg2010: 139: 1576–1586.
11.
CorveraJSKinHDobsonGP. Polarized arrest with warm or cold adenosine/lidocaine blood cardioplegia is equivalent to hypothermic potassium blood cardioplegia. J Thorac Cardiovasc Surg2005; 129: 599–606.
12.
OnoratiFSantiniFDandaleR. “Polarizing” microplegia improves cardiac cycle efficiency after CABG for unstable angina. Int J Cardiol2013; 167: 2739–2746.
13.
JinZZhangSWangX. The myocardial protective effects of a moderate-potassium adenosine–lidocaine cardioplegia in pediatric cardiac surgery. J Thorac Cardiovasc Surg2008; 136: 1450–1455.
14.
O’RullianJJClaysonSEPeragalloR. Excellent outcomes in a case of complex re-do surgery requiring prolonged cardioplegia using a new cardioprotective approach: adenocaine. J Extracorp Technol2008; 40: 203–205.